Search Results
Your search for all items matches 775 pages
Showing 1 - 50Addition of Pemetrexed/Carboplatin to Gefitinib in Advanced EGFR-Mutant NSCLC
In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Noronha et al found that the addition of pemetrexed/carboplatin to gefitinib improved progression-free and overall survival in first-line treatment of advanced EGFR-mutant non–small cell lung cancer...
Pooled Analysis of 4-Year Survival With Nivolumab Therapy in Patients With Previously Treated Advanced NSCLC
In an analysis reported in The Lancet Oncology, Antonia et al identified long-term survival rates with nivolumab therapy in patients with previously treated advanced non–small cell lung cancer (NSCLC). The pooled analysis included data from the CheckMate 017, 057, 063, and 003 trials, each...
FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (Rozlytrek) for adult and adolescent patients whose cancers have an NTRK (neurotrophic tyrosine receptor kinase) genetic fusion and for whom there are no effective treatments. Entrectinib was also...
Olaparib/Temozolomide Shows Activity in Patients With Relapsed Small Cell Lung Cancer
Small cell lung cancer accounts for approximately 15% of all lung cancers and has high metastatic potential and poor clinical outcomes. While untreated small cell lung cancers are usually highly sensitive to cytotoxic chemotherapy—with response rates of between 50% and 70%—patients...
Addition of Cediranib to Cisplatin/Pemetrexed in Chemotherapy-Naive Unresectable Malignant Pleural Mesothelioma
In the phase II SWOG S0905 trial reported in the Journal of Clinical Oncology, Tsao et al found that the addition of the epidermal growth factor receptor and platelet-derived growth factor receptor inhibitor cediranib to cisplatin/pemetrexed was associated with limited benefit and greater toxicity...
Maintenance Bevacizumab, Pemetrexed, or Both in Advanced Nonsquamous NSCLC
In the phase III ECOG-ACRIN 5508 trial, reported in the Journal of Clinical Oncology by Ramalingam et al, maintenance pemetrexed or bevacizumab was associated with no significant improvement in overall survival vs the bevacizumab control group alone, and was associated with greater toxicity in...
Five-Year Survival in Heavily Pretreated Patients Receiving Nivolumab Monotherapy
As reported by Topalian et al in JAMA Oncology, long-term follow up of patients from a phase I expansion cohort study indicated 5-year overall survival rates of 34.2%, 27.7%, and 15.6% among patients who received nivolumab monotherapy for advanced melanoma, renal cell carcinoma (RCC), and...
FDA Pipeline: Label Update for Durvalumab in NSCLC; Applications Accepted in Epithelioid Sarcoma, AML
Recently, the U.S. Food and Drug Administration (FDA) approved the inclusion of overall survival from the PACIFIC trial in the U.S. prescribing information for durvalumab and accepted applications for a new drug in the treatment of epithelioid sarcoma and two orphan drugs in the treatment of acute...
Deep Natural Language Processing of Oncology Radiology Reports
Scientists have demonstrated that an artificial intelligence (AI) tool can perform as well as human reviewers—and much more rapidly—in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer. These findings were...
Pembrolizumab After Stereotactic Body Radiotherapy in Advanced NSCLC
In a Dutch phase II study reported in JAMA Oncology, Theelen et al found that although use of stereotactic body radiotherapy prior to pembrolizumab increased the objective response rate vs pembrolizumab alone in metastatic non–small cell lung cancer (NSCLC), the difference did not meet study...
Immunotherapy After Locally Ablative Therapy for Oligometastatic NSCLC
In a single-center phase II trial reported in JAMA Oncology, Bauml et al found that pembrolizumab given after locally ablative therapy appeared to be associated with improved outcomes in patients with oligometastatic non–small cell lung cancer (NSCLC). In the study, 45 evaluable...
Poorer Outcomes for Patients With Lung Cancer Undergoing Radiotherapy During Disaster-Level Hurricanes
Patients who experienced a disaster-level hurricance during radiotherapy for lung cancer had worse overall survival than those who completed treatment in normal circumstances, with longer disaster declarations associated with increasingly worse survival. These findings come from a...
Ramucirumab Plus Pembrolizumab in Previously Treated Advanced Gastroesophageal Cancer, NSCLC, and Urothelial Carcinoma
Results from a phase IB trial expansion stage reported in The Lancet Oncology by Herbst et al showed the combination of ramucirumab plus pembrolizumab had manageable toxicity and antitumor activity in previously treated advanced gastroesophageal cancer, non–small cell lung cancer (NSCLC), and ...
FDA Pipeline: Designations and Applications Granted in Lymphoma, Small Cell Lung Cancer, Multiple Myeloma, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a phospholipid-drug conjugate in diffuse large B-cell lymphoma; granted Orphan Drug designation to an immunotherapy for small cell lung cancer (SCLC); accepted supplemental biologics license applications (sBLAs) ...
Cost-Effectiveness of Single-Marker Genetic Testing vs Multigene Panel Sequencing in Advanced NSCLC
The results of an economic modeling study to estimate the cost-effectiveness of multigene panel sequencing as compared to standard-of-care single-gene tests for patients with advanced non–small cell lung cancer (NSCLC) showed that multigene panel sequencing tests are moderately...
Risk-Prediction Model Aims to Predict Incident Lung Cancer in Patients With a Pulmonary Nodule
A risk-prediction model developed using clinical and radiologic features could stratify individuals presenting with a lung nodule as having a high or low risk for lung cancer, according to a study published by Nemesure et al in Cancer Prevention Research. “While lung nodules are not...
Frequency, Complications, and Costs of Diagnostic and Postprogression Biopsies in NSCLC
In a retrospective study reported in the Journal of Oncology Practice, Kelly et al identified the frequency of diagnostic and postprogression biopsies, complication rates, and associated costs in patients with non–small cell lung cancer (NSCLC). The study involved patient data from the...
Do Statins Lower the Risk of Cardiovascular Complications in Patients Treated With Radiotherapy to the Chest, Neck, or Head?
Patients with cancer who took cholesterol-lowering statin medication following radiation therapy of the chest, neck, or head had significantly reduced risk of suffering a stroke—and possibly other cardiovascular complications—according to research published by Boulet et al in...
Extended Follow-up From the National Lung Screening Trial Reported
Early detection and treatment through screening with low-dose computed tomography (LDCT) has been investigated as a potential means of reducing lung cancer mortality for more than 2 decades. In 2011, a large U.S. study—the randomized National Lung Screening Trial (NLST)—reported a 20%...
FDA Approves Bevacizumab Biosimilar for Five Cancer Types
On June 28, the U.S. Food and Drug Administration (FDA) approved bevacizumab-bvzr (Zirabev), a biosimilar to bevacizumab (Avastin), for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent, or metastatic nonsquamous non–small cell ...
Outcomes of Immune Checkpoint Inhibitor Treatment in Patients With Advanced NSCLC Receiving Baseline Corticosteroids
In a single-center study reported in the Journal of Clinical Oncology, Ricciuti et al found better outcomes with immune checkpoint inhibitor treatment among patients with advanced non–small cell lung cancer (NSCLC) receiving baseline prednisone equivalent of ≥ 10 mg daily for...
FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies
On June 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti–programmed cell death protein 1 (PD-1) therapy pembrolizumab (Keytruda) as monotherapy for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease...
Radiotherapy Increases Adverse Cardiovascular Event Risk for Patients With Lung Cancer
A new retrospective study led by investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute examined outcomes for patients after receiving treatment for locally advanced non–small cell lung cancer (NSCLC), finding that the average radiation dose delivered to the...
KEYNOTE-001: 5-Year Overall Survival With Pembrolizumab in Advanced NSCLC
Long-term follow-up of the phase I KEYNOTE-001 study reported in the Journal of Clinical Oncology by Garon et al showed that pembrolizumab monotherapy was associated with an estimated 5-year overall survival of 23.2% for treatment-naive patients and 15.5% for previously treated patients with...
2019 ASCO: NEOSTAR: Neoadjuvant Nivolumab Plus Ipilimumab in Early-Stage, Resectable NSCLC
Neoadjuvant treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33% of treated patients with early-stage, resectable non–small cell lung cancer (NSCLC). With these results, the combination immunotherapy met the prespecified trial...
IMpower130: Addition of First-Line Atezolizumab to Chemotherapy in Metastatic Nonsquamous NSCLC
As reported in The Lancet Oncology by West et al, the phase III IMpower130 trial found that the addition of atezolizumab to carboplatin plus nab-paclitaxel significantly improved overall and progression-free survival in first-line treatment of stage IV nonsquamous non–small cell lung cancer...
2019 ASCO: Expansion of Clinical Trial Inclusion Criteria in Patients With Advanced NSCLC
A study that examined 10,500 health records of patients with advanced non–small cell lung cancer from ASCO’s CancerLinQ database found that the use of expanded clinical trial inclusion criteria—as proposed by ASCO and Friends of Cancer Research in 2017—would nearly double...
2019 ASCO: KEYNOTE-001: 5-Year Survival Data for Patients With Advanced NSCLC Treated With Pembrolizumab
Five-year data from the phase Ib KEYNOTE-001 trial showed that treatment with pembrolizumab was safe and effective and substantially increased overall survival in patients with advanced non–small cell lung cancer (NSCLC). Specifically, 23.2% of people who had not previously been treated with...
Addition of Bevacizumab to Carboplatin/Pemetrexed in Nonsquamous NSCLC
New research published by Bagley et al in JNCCN—Journal of the National Comprehensive Cancer Network used a large real-world data set to demonstrate a modest but consistent survival benefit associated with adding bevacizumab to carboplatin/pemetrexed in advanced nonsquamous non–small...
FDA Approves the NovoTTF-100L System in Combination With Chemotherapy for Malignant Pleural Mesothelioma
On May 23, the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable locally advanced or metastatic malignant pleural mesothelioma. NovoTTF-100L is a noninvasive,...
ACCURE Trial: Improving Racial Disparities in Treatment for Patients With Early-Stage Lung and Breast Cancers
Results from a study published by Cykert et al in The Journal of the National Medical Association show that a pragmatic system-based intervention within cancer treatment centers can nearly eliminate existing disparities in treatment and outcomes for black patients with early-stage...
Long-Term Results With Local Consolidative Therapy vs Maintenance Therapy or Observation in Oligometastatic NSCLC
In long-term follow-up of a phase II study reported in the Journal of Clinical Oncology, Gomez et al confirmed superior outcomes with local consolidative therapy vs maintenance therapy or observation in patients with oligometastatic non–small cell lung cancer (NSCLC). In the open-label,...
Lifetime Risk of Brain Metastases in Elderly Survivors of Breast, Lung, and Skin Cancers
Elderly survivors of breast cancer, lung cancer, and melanoma face risk of brain metastasis later in life, and may require extra surveillance in the years following initial cancer treatment, according to results of a study published by Ascha et al in Cancer Epidemiology, Biomarkers, &...
Association Between Clinical Outcomes and Patient Characteristics/Genomic Profiles in Lung Cancer
As reported in JAMA, Singal et al used a clinicogenomic database in routine clinical practice to identify associations between treatment outcomes and patient characteristics or tumor genomic profiles in the setting of non–small cell lung cancer (NSCLC). The study cohort of 4,064 patients...
ESTRO 38: Radical Hemithoracic Therapy in Patients With Mesothelioma
Patients with mesothelioma are twice as likely to survive for 2 years or longer if they are treated with a high dose of radiation to the affected side of the trunk, according to research presented by Minatel et al at ESTRO 38, the annual congress of the European Society for Radiotherapy...
Survey Finds Rates of Physician-Patient Discussions About Lung Cancer Screening Are Declining
A study examining trends in patient-reported physician-patient discussions about lung cancer screening and the association of these discussions with smokers’ attempts to quit and intent to quit has found that discussions about screening have declined since 2012. Moreover, they were not...
Erlotinib Plus Bevacizumab vs Erlotinib Alone in EGFR-Positive, Advanced Nonsquamous NSCLC
In an interim analysis of the phase III NEJ026 trial reported in The Lancet Oncology, Saito et al found that the addition of bevacizumab to erlotinib improved progression-free survival in patients with EGFR-positive, nonsquamous non–small cell lung cancer (NSCLC). In the open-label...
Combined Crowd Innovation and AI in Producing Algorithms for Radiotherapy Targeting
In a study reported in JAMA Oncology, Mak et al found that a crowd innovation contest produced automated artificial intelligence (AI) algorithms “that replicated the skills of a highly trained physician” in segmenting lung tumors for radiotherapy targeting. The investigators also noted...
Deep-Learning Model May Improve Predictions of Survival and Specific Outcomes in Lung Cancer
A study by Xu et al in Clinical Cancer Research evaluating deep-learning networks that analyze time-series computed tomography (CT) images of patients with locally advanced NSCLC has found these networks can integrate imaging scans at multiple time points to improve clinical outcome...
KEYNOTE-042: Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic NSCLC With PD-L1 Expression ≥ 1%
As reported in The Lancet by Mok et al, the KEYNOTE-042 trial has shown an improvement in overall survival with pembrolizumab vs standard chemotherapy in previously untreated patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) without a sensitizing EGFR mutation or ...
Five-Fraction SBRT for Centrally Located, Inoperable NSCLC
In the phase I/II NRG Oncology/RTOG 0813 study reported in the Journal of Clinical Oncology, Bezjak et al found that five-fraction stereotactic body radiotherapy (SBRT) was associated with relatively low rates of serious treatment-related toxicity and good outcomes in patients with centrally...
Prophylactic Irradiation of Chest Wall Procedure Sites in Malignant Pleural Mesothelioma
In a phase III trial reported in the Journal of Clinical Oncology, Bayman et al found that prophylactic radiotherapy to the chest wall after diagnostic or therapeutic procedures did not reduce the risk of chest wall metastases in patients with malignant pleural mesothelioma. In the open-label,...
FDA Expands Pembrolizumab Indication for NSCLC in First-Line Setting
Today, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the first-line treatment of patients with stage III non–small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or those with metastatic NSCLC....
ELCC 2019: Does Maintenance Immunotherapy Improve Survival in Patients With Advanced SCLC?
Maintenance immunotherapy did not improve survival in patients with extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study presented today by Owonikoko et al at the European Lung Cancer Congress 2019 (Abstract LBA1_PR). Around 60% to 70% of...
ELCC 2019: Immunotherapy in Elderly Patients With Advanced NSCLC
Two studies reported at the European Lung Cancer Congress (ELCC) 2019 provided new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non–small cell lung cancer (NSCLC). Although around half of all people newly diagnosed with NSCLC are elderly (Pallis ...
Lung Cancer Organizations Join Forces to Launch GO2 Foundation for Lung Cancer
Two nonprofit organizations serving the lung cancer community—the Bonnie J. Addario Lung Cancer Foundation (ALCF) and Lung Cancer Alliance (LCA)—have announced they are joining forces as the GO2 Foundation for Lung Cancer. With more than 3 decades of combined expertise, a...
Effect of Increased VA Hospice Care on Use of Aggressive Care and Costs for Veterans With Advanced Lung Cancer
In a study reported in JAMA Oncology, Mor et al found that veterans with advanced lung cancer treated in Veterans Affairs (VA) Medical Centers with high hospice use were more likely to receive concurrent cancer care but less likely to receive aggressive care. Moreover, veterans treated at...
Long-Term Outcomes for Prophylactic Cranial Irradiation vs Observation in Locally Advanced NSCLC
As reported in JAMA Oncology by Sun et al, a long-term update of the phase III NRG Oncology/RTOG 0214 trial has shown that prophylactic cranial irradiation was associated with a reduced incidence of brain metastases and improved disease-free survival—but not overall survival—compared...
AACR 2019: Data Analysis Shows Activity of Pembrolizumab in Pretreated Patients With Advanced Small Cell Lung Cancer
The results of an analysis of pooled data from the phase Ib KEYNOTE-028 trial and the phase II KEYNOTE-158 study of the anti–programmed cell death protein 1 monoclonal antibody pembrolizumab in the treatment of advanced small cell lung cancer has found that the therapy provided antitumor...
Lorlatinib in Advanced NSCLC With ALK Resistance Mutations
In a study reported in the Journal of Clinical Oncology, Shaw et al found that lorlatinib showed greater efficacy in patients with vs without anaplastic lymphoma kinase (ALK) resistance mutations among patients with advanced ALK-positive non–small cell lung cancer (NSCLC) in whom one or more...
